[Disclosure] Alteogen (196170) Signs Exclusive License Agreement with AstraZeneca Subsidiary for ALT-B4 Valued up to USD 750M (KRW 1.09T)

Source Fact: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-03-17

Disclosure Type: Major Management Matters Related to Investment Decisions

💡 3-Second Summary

Alteogen has entered into an exclusive license agreement with MedImmune Limited, a subsidiary of global pharmaceutical giant AstraZeneca, to develop and commercialize a subcutaneous (SC) formulation of an AstraZeneca oncology therapeutic utilizing Alteogen’s ALT-B4 technology. The total transaction value reaches up to USD 750,000,000 (approx. KRW 1.09T), featuring a non-refundable upfront payment of USD 25,000,000 (approx. KRW 36.37B) to be received within 30 days.

📊 1. [Summary of Core Disclosure Content and Key Figures]

• Counterpart: MedImmune Limited (UK, a global biologics R&D subsidiary of AstraZeneca / AstraZeneca’s recent annual revenue: US$ 54,073M)
• Scope of Agreement: An exclusive license agreement for the development and commercialization of a subcutaneous formulation of an AstraZeneca oncology product applying Alteogen’s Hybrozyme platform-based human hyaluronidase (ALT-B4).
• Execution Date & Contract Period: Signed on March 15, 2025 / Effective from March 17, 2025, until the expiration of the royalty period.
• Financial Details (Applied Foreign Exchange Rate: KRW 1,454.8/USD based on the Seoul Foreign Forex Brokerage notice on March 17, 2025):
  • Maximum Potential Contract Value: Up to US$ 750,000,000 (approx. KRW 1,091,100,000,000 / Sales royalties are separate)
    1. Upfront Payment: US$ 25,000,000 (KRW 36,370,000,000) – Equivalent to 37.68% of Alteogen’s 2023 consolidated annual revenue (KRW 96,523M)
    2. Milestone Payments: Up to US$ 725,000,000 (KRW 1,054,730,000,000) – To be received upon attaining specific clinical, regulatory approval, and commercialization milestones for two products utilizing ALT-B4.
    3. Sales Royalties: Running royalties representing a specified percentage of net sales after the first commercial sale of the product.
• Payment and Settlement Terms: The upfront payment is scheduled to be received within 30 days from the effective date (prior to April 16, 2025). There is no obligation to return any upfront, milestone, or royalty fees received, even if the project is terminated.
• Board Resolution Date: March 15, 2025 (Attended by 2 outside directors and the internal auditor).
• Information Deferral & Risk Factors: Specific breakdowns of milestone allocations and the name of the development product are deferred from public disclosure until contract termination due to confidentiality clauses. The agreement may be terminated prematurely due to the counterpart’s convenience, material breach, or insolvency.

📈 2. [Expert Perspective: What This Disclosure Means for Investors]

This regulatory filing functions as an official announcement verifying that Alteogen’s proprietary ALT-B4 platform has been exclusively integrated into critical oncology assets managed by AstraZeneca. From a technical metric standpoint, the non-refundable upfront allocation alone guarantees an influx of approximately KRW 36.37B within 30 days—exceeding 37% of the prior annual consolidated revenue—which could introduce a positive potential impact on short-term liquidity management and internal cash positions.

Investors should monitor the incremental milestone structure of up to USD 725M and consecutive sales royalties as key long-term variables that may alter the company’s business fundamentals. However, as underscored in the notice, this transaction is a conditional contract contingent upon definitive marketing authorizations from relevant regulatory bodies. Clinical trial limitations, failure to obtain regulatory approvals, or mid-term cancellations for the counterpart’s convenience may diminish the projected cash inflows or terminate the contract entirely. Consequently, rather than analyzing unverified forward-looking milestones as absolute facts, investors are advised to focus objectively on the confirmed upfront baseline and the strategic nature of this exclusive partnership while tracking the operational implementation timelines.

📝 Editor’s Comment (by K-STOCK Editor)

Alteogen’s ALT-B4 platform has marked another technical milestone by securing an exclusive validation from a top-tier global pharmaceutical player. This agreement with AstraZeneca’s UK R&D subsidiary guarantees a non-refundable upfront cash injection of USD 25 million within 30 days, fortifying the parent company’s near-term capital reserves. While specific target details and milestone tranches remain under regulatory nondisclosure until contract termination and clinical uncertainties persist, the technical endorsement of their subcutaneous formulation platform for two separate products is a confirmed operational milestone. Market participants should prioritize tracking the non-refundable terms and documented progress parameters moving forward.

📢 Disclaimer and Source Information

Source: This content has been newly structured and written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for information and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Inquiries: For compliance-related inquiries or copyright requests, please contact ksb220805@gmail.com.